hematoporphyrin monomethyl ether
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started May 17, 2017 (NCT03125057)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- contrast mediumContrast agent
contrast medium contrast agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hematoporphyrin monomethyl ether
- hemoporfin
- hemoporfin
- hemoporfin
- hmme cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04860154 | N/A | Apr 17, 2021 | Hepatopancreatobiliary Surgery Institute of Gansu Province |
| NCT03181984 | Phase 4 | Jun 1, 2017 | Peking University, Shanghai Zhangjiang Biotechnology Limited Company |
| NCT03125057 | Phase 4 | May 17, 2017 | Capital Medical University, Shanghai Zhangjiang Biotechnology Limited Company |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Zhangjiang Biotechnology Limited Company | For profit | 2 | 2 | 1 | 2017 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Hepatopancreatobiliary Surgery Institute of Gansu Province | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1